DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Apadaz is a drug marketed by Kvk Tech Inc and is included in one NDA. There are five patents protecting this drug.
This drug has thirty-five patent family members in twenty countries.
The generic ingredient in APADAZ is acetaminophen; benzhydrocodone hydrochloride. There are sixty-six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the acetaminophen; benzhydrocodone hydrochloride profile page.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be February 22, 2031. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Generic Entry Opportunity Date for APADAZ
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||TE||Type||RLD||RS||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Exclusivity Expiration|
|Kvk Tech Inc||APADAZ||acetaminophen; benzhydrocodone hydrochloride||TABLET;ORAL||208653-002||Jan 4, 2019||RX||Yes||No||Start Trial||Start Trial||Y||Y||Start Trial|
|Kvk Tech Inc||APADAZ||acetaminophen; benzhydrocodone hydrochloride||TABLET;ORAL||208653-001||Feb 23, 2018||RX||Yes||No||Start Trial||Start Trial||Y||Y||Start Trial|
|Kvk Tech Inc||APADAZ||acetaminophen; benzhydrocodone hydrochloride||TABLET;ORAL||208653-002||Jan 4, 2019||RX||Yes||No||Start Trial||Start Trial||Y||Start Trial|
|>Applicant||>Tradename||>Generic Name||>Dosage||>NDA||>Approval Date||>TE||>Type||>RLD||>RS||>Patent No.||>Patent Expiration||>Product||>Substance||>Delist Req.||>Exclusivity Expiration|